Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32674614 | 1.00 | KDM4E (0.32) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL6950633 | 0.82 | CDK1 (0.30) | — | |
| SCHEMBL10852256 | 0.81 | — | — | |
| SCHEMBL14993000 | 0.81 | KDM4E (0.32) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2640834 | 0.80 | APLNR (0.33) | — | |
| SCHEMBL28793534 | 0.78 | KDM4E (0.34) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12413624 | 0.75 | LMNA (0.32) | — | |
| SCHEMBL2640870 | 0.75 | — | — | |
| SCHEMBL375954 | 0.74 | PDK2 (0.40) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL7943071 | 0.73 | KDM4E (0.30) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876474-A | Dimethoxy tetrahydroisoquinoline substituted purine derivative, preparation method thereof and application thereof in antitumor drugs | 林剑雄 | 2021-06-01 | — | — | CN | claimed |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2020-12-15 | — | — | US | claimed |
| US-12312642-B2 | Method for the diagnosis, prognosis and treatment of breast cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES) | 2025-05-27 | — | — | US | disclosed |
| US-20250115912-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2025-04-10 | — | — | US | disclosed |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) and INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ES) | 2025-01-14 | — | — | US | disclosed |
| US-11892453-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2024-02-06 | — | — | US | disclosed |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | INBIOMOTION S.L. (ES) | 2023-12-12 | — | — | US | disclosed |
| US-20230323356-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2023-10-12 | — | — | US | disclosed |
| US-11591599-B2 | Method for the diagnosis, prognosis and treatment of cancer metastasis | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2023-02-28 | — | — | US | disclosed |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) | 2022-06-07 | — | — | US | disclosed |
| US-20220049316-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES) | 2022-02-17 | — | — | US | disclosed |
| US-7745450-B2 | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy | INSTITUTE OF EXPERIMENTAL BOTANY (CZ) | 2010-06-29 | — | — | US | disclosed |
| EP-1802310-A1 | USE OF PURINE DERIVATIVES FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES RELATED TO PROTEIN ADDRESSING ERRORS IN CELLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006042949-A1 | USE OF PURINE DERIVATIVES FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES RELATED TO PROTEIN ADDRESSING ERRORS IN CELLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-04-27 | — | — | WO | disclosed |
| US-20050159432-A1 | Short form c-Maf transcription factor antagonists for treatment of glaucoma | ALCON, INC. (CH) | 2005-07-21 | — | — | US | disclosed |
| US-20050136043-A1 | TGFbeta signaling inhibitors | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2005-06-23 | — | — | US | disclosed |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF | 2005-04-14 | — | — | US | disclosed |
| EP-1147108-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043394-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000033657-A1 | METHOD TO IDENTIFY REGULATORS OF CDK ACTIVITY | CROPDESIGN N.V. (BE) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136043-A1 | TGFbeta signaling inhibitors | TGFBR1, TGFBR2, TGFB1 | KDM4E 2159/4885ALDH1A1 4561/4885GLA 1142/4885 |
| US-20230323356-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, RHOXF2, MAFK | KDM4E 2686/4885ALDH1A1 3426/4885GLA 1703/4885 |
| US-20050080097-A1 | Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy | CBR3, DHFR, AKR1C3 | KDM4E 4054/4885ALDH1A1 1092/4885GLA 3631/4885 |
| US-11892453-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, MAFK, ACP3 | KDM4E 1212/4885ALDH1A1 2286/4885GLA 3072/4885 |
| US-12196758-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | KDM4E 1102/4885ALDH1A1 1914/4885GLA 2032/4885 |
| US-11591599-B2 | Method for the diagnosis, prognosis and treatment of cancer metastasis | MAFG, RHOXF2, MAFK | KDM4E 2686/4885ALDH1A1 3426/4885GLA 1703/4885 |
| US-20220049316-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | MAFG, MAFK, CRACR2A | KDM4E 844/4885ALDH1A1 2951/4885GLA 3407/4885 |
| US-11840740-B2 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | MAFG, ACP3, MAFK | KDM4E 1118/4885ALDH1A1 1738/4885GLA 2563/4885 |
| US-20250115912-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | MAFG, RHOXF2, MAFK | KDM4E 2686/4885ALDH1A1 3426/4885GLA 1703/4885 |
| US-11352673-B2 | Method for the diagnosis, prognosis and treatment of lung cancer metastasis | MAFG, MAFK, MYCBP | KDM4E 1304/4885ALDH1A1 2678/4885GLA 3488/4885 |
| US-10866241-B2 | Method for the prognosis and treatment of cancer metastasis | MAFG, BRCA1, BCOR | KDM4E 1102/4885ALDH1A1 1914/4885GLA 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.